Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 10 2023 - 12:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 10 March 2023, London UK
GSK plc
Annual Report 2022 on Form 20-F
In accordance with Section 203.01 of the New York Stock Exchange
Listed Company Manual, GSK plc ("GSK") announces that on 10 March
2023 it filed with the Securities and Exchange Commission an Annual
Report on Form 20-F that included audited financial statements for
the year ended 31 December 2022. GSK's 2022 Annual Report on Form
20-F is available online at GSK's website at www.gsk.com/corporatereporting and
also online at www.sec.gov.
A hard copy version of the GSK 2022 Annual Report, together with
the Notice of Annual General Meeting will be available on or about
27 March 2023.
Shareholders have the ability to receive, upon request, a hard copy
version of GSK's complete audited financial statements for the year
ended 31 December 2022, free of charge, by either:
(i)
|
writing to Equiniti Limited, our registrars in the UK, at the
following address: Equiniti Limited, Aspect House, Spencer
Road, Lancing, West Sussex BN99 6DA, or by telephone on +44 (0)371
384 2991 (please use the area code if calling from outside the
UK);
|
(ii)
|
writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the
US, at the following address: EQ Shareowner Services, P.O. Box
64504, St. Paul, MN 55164-0504, or by telephone on +1 877 353 1154
(US toll free) or +1 651 453 2128 (outside the US); or
|
(iii)
|
contacting the GSK Response Center in the USA at +1 888 825 5249
(US toll free).
|
Victoria Whyte
Company Secretary
10 March 2023
Cautionary statement regarding forward-looking statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors" in the company's Annual Report on Form 20-F for
2022, GSK's Q4 Results for 2022 and any impacts of the COVID-19
pandemic.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: March
10, 2023
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024